Characterization of various nanoparticle formulations
| Formulation . | Particle size, nm* . | Zeta potential, mV . |
|---|---|---|
| Naked nanoparticles | 49.3 ± 5.2 | 4.22 ± 0.82 |
| HER-INPs | 55.6 ± 7.4 | 4.25 ± 0.65 |
| RIT-INPs | 56.3 ± 7.5 | 2.09 ± 0.31 |
| Formulation . | Particle size, nm* . | Zeta potential, mV . |
|---|---|---|
| Naked nanoparticles | 49.3 ± 5.2 | 4.22 ± 0.82 |
| HER-INPs | 55.6 ± 7.4 | 4.25 ± 0.65 |
| RIT-INPs | 56.3 ± 7.5 | 2.09 ± 0.31 |
Molar ratio of ILPs was 3β-N-(N′,N′-dimethyl amino ethane)-carbamoyl cholesterol/egg phosphatidylcholine/methoxy polyethylene glycol–distearoyl phosphatidylethanolamine = 28/70/2; weight ratio was lipids/ODN/protamine = 12.5/1/0.3; 0.05 mol % Herceptin or rituximab was conjugated on INPs. The encapsulation efficiency of ODNs was above 90%.
The representative data are from the mean of 3 separate measurements.